Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.34 |
| ▸ | CDK2 | P24941 | 12/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 7/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16224064 | 1.00 | EPHX1 (0.37) | EPHX1DPP4CCNE1CDK2SMN1; SMN2 | |
| SCHEMBL2145078 | 1.00 | EPHX1 (0.37) | EPHX1DPP4CCNE1CDK2SMN1; SMN2 | |
| SCHEMBL25270786 | 0.93 | EPHX1 (0.40) | EPHX1DPP4CCNE1CDK2SMN1; SMN2 | |
| SCHEMBL27855976 | 0.91 | NAAA (0.35) | EPHX1DPP4CCNE1CDK2GSK3B | |
| SCHEMBL7815595 | 0.90 | EPHX1 (0.42) | EPHX1DPP4CCNE1CDK2SMN1; SMN2 | |
| SCHEMBL23437012 | 0.89 | EPHX1 (0.42) | EPHX1DPP4SMN1; SMN2APOBEC3AAPOBEC3G | |
| SCHEMBL25281021 | 0.89 | CCNE1 (0.37) | DPP4CCNE1CDK2GSK3B | |
| SCHEMBL25271862 | 0.89 | CCNE1 (0.37) | DPP4CCNE1CDK2GSK3B | |
| SCHEMBL27760444 | 0.89 | CCNE1 (0.37) | DPP4CCNE1CDK2GSK3B | |
| Methane SCHEMBL27968861 | 0.88 | EPHX1 (0.41) | EPHX1DPP4CCNE1CDK2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076581-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
| CN-107200749-B | DNA-PK inhibitor | 沃泰克斯药物股份有限公司 | 2019-09-03 | — | — | CN | disclosed |
| CN-109966294-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维爱尔兰无限公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-109897038-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维爱尔兰无限公司 | 2019-06-18 | — | — | CN | disclosed |
| US-10273242-B2 | Compound inhibiting activities of BTK and/or JAK3 kinases | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2019-04-30 | — | — | US | disclosed |
| CN-109180702-A | A kind of Thienopyrimidine ketone compound and application thereof | 四川大学 | 2019-01-11 | — | — | CN | disclosed |
| CN-108473471-A | Substituted thiourocystine derivatives as androgen receptor antagonists | 詹森药业有限公司 | 2018-08-31 | — | — | CN | disclosed |
| US-20180051036-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2018-02-22 | — | — | US | disclosed |
| US-9840517-B2 | Compound inhibiting activities of BTK and/or JAK3 kinases | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2017-12-12 | — | — | US | disclosed |
| CN-1829712-A | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER (US) | 2006-09-06 | — | — | CN | disclosed |
| CN-1652782-A | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER (US) | 2005-08-10 | — | — | CN | disclosed |
| CN-1582281-A | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO LTD (JP) | 2005-02-16 | — | — | CN | disclosed |
| CN-1578779-A | Small organic molecule regulators of cell proliferation | CURIS INC (US) | 2005-02-09 | — | — | CN | disclosed |
| US-6096751-A | INSECTICIDES, PARASITICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-08-01 | — | — | US | disclosed |
| US-6054459-A | INSECTICIDES AND ECTOPARASITICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-04-25 | — | — | US | disclosed |
| EP-0740666-B1 | SUBSTITUTED 1,2,3,4-TETRAHYDRO-5-NITRO PYRIMIDINES | BAYER AG (DE) | 1999-11-10 | — | — | EP | disclosed |
| US-5869491-A | PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-02-09 | — | — | US | disclosed |
| EP-0740666-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRO-5-NITRO PYRIMIDINES | BAYER AG (DE) | 1996-11-06 | — | — | EP | disclosed |
| WO-1995019977-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRO-5-NITRO PYRIMIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051036-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | BTK, JAK3, JAK2 | EPHX1 3827/4885DPP4 2607/4885CCNE1 3090/4885 |
| US-10273242-B2 | Compound inhibiting activities of BTK and/or JAK3 kinases | BTK, JAK3, JAK2 | EPHX1 3827/4885DPP4 2607/4885CCNE1 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.